These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Teriflunomide: a review of its use in relapsing multiple sclerosis. Garnock-Jones KP CNS Drugs; 2013 Dec; 27(12):1103-23. PubMed ID: 24198223 [TBL] [Abstract][Full Text] [Related]
25. Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. Iglesias-Bregna D; Hanak S; Ji Z; Petty M; Liu L; Zhang D; McMonagle-Strucko K J Pharmacol Exp Ther; 2013 Oct; 347(1):203-11. PubMed ID: 23892570 [TBL] [Abstract][Full Text] [Related]
26. ▼Teriflunomide for multiple sclerosis. Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149 [TBL] [Abstract][Full Text] [Related]
27. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Vermersch P; Czlonkowska A; Grimaldi LM; Confavreux C; Comi G; Kappos L; Olsson TP; Benamor M; Bauer D; Truffinet P; Church M; Miller AE; Wolinsky JS; Freedman MS; O'Connor P; Mult Scler; 2014 May; 20(6):705-16. PubMed ID: 24126064 [TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis. Guarnera C; Bramanti P; Mazzon E Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828 [TBL] [Abstract][Full Text] [Related]
29. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis. Kretzschmar B; Pellkofer H; Weber MS Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956 [TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS; Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517 [TBL] [Abstract][Full Text] [Related]
31. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. O'Connor P; Wolinsky JS; Confavreux C; Comi G; Kappos L; Olsson TP; Benzerdjeb H; Truffinet P; Wang L; Miller A; Freedman MS; N Engl J Med; 2011 Oct; 365(14):1293-303. PubMed ID: 21991951 [TBL] [Abstract][Full Text] [Related]
32. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Fragoso YD; Brooks JB Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857 [TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis. Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698 [TBL] [Abstract][Full Text] [Related]
34. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells. Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N Front Immunol; 2021; 12():730342. PubMed ID: 34721394 [TBL] [Abstract][Full Text] [Related]
35. Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. Comi G; Freedman MS; Meca-Lallana JE; Vermersch P; Kim BJ; Parajeles A; Edwards KR; Gold R; Korideck H; Chavin J; Poole EM; Coyle PK BMC Neurol; 2020 Oct; 20(1):364. PubMed ID: 33023488 [TBL] [Abstract][Full Text] [Related]
36. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. Comi G; Miller AE; Benamor M; Truffinet P; Poole EM; Freedman MS Mult Scler; 2020 Aug; 26(9):1083-1092. PubMed ID: 31172849 [TBL] [Abstract][Full Text] [Related]
37. Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report. Ferreira CM; Vasconcelos-Pereira EF; Oliveira VM; Salgado PR; Domingos JA; Monreal MTFD; Guerra-Shinohara EM; Gubert VT Medicine (Baltimore); 2021 Dec; 100(51):e28246. PubMed ID: 34941096 [TBL] [Abstract][Full Text] [Related]
38. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW; Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860 [TBL] [Abstract][Full Text] [Related]
39. Ofatumumab versus Teriflunomide in Multiple Sclerosis. Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L; N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523 [TBL] [Abstract][Full Text] [Related]
40. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]